title: Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?
abstract: Treatment with regorafenib has demonstrated statistically significant improvements in terms of overall survival, progression-free survival and disease control when compared with placebo in pretreated patients with metastatic colorectal cancer in two placebo-controlled, randomized, phase III trials (CORRECT and CONCUR). Similar results were observed in two open-label, single-arm studies (REBECCA and CONSIGN) performed in the real-world setting. But several authors have suggested that the benefit provided by regorafenib may not be clinically meaningful for these patients. Moreover, it has been suggested that not all subgroups of patients might benefit from regorafenib. The intention of this review is to provide an overview of the existing evidence for regorafenib in terms of efficacy, tolerability and quality of life in different subpopulations according to clinical and biological characteristics. Additionally, the magnitude of the clinical benefit provided by regorafenib to these patients has been explored and whether there are poorer outcomes in certain subpopulations.
authors.affiliation: Medical Oncology Department, Gregorio Marañón University Hospital (Center Affiliated to the Red Tematica de Investigacion Cooperativa en Cancer [RTICC], Instituto Carlos III, Spanish Ministry of Science and Innovation), Madrid, Spain. pgarcaalfonso@gmail.com.
authors.forename: P
authors.initials: P
authors.lastname: García-Alfonso
authors.affiliation: Medical Oncology Department, La Paz University Hospital, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Feliú
authors.affiliation: Medical Oncology Department, Doce de Octubre University Hospital (Center Affiliated to the Red Tematica de Investigacion Cooperativa en Cancer [RTICC], Instituto Carlos III, Spanish Ministry of Science and Innovation), Madrid, Spain.
authors.forename: R
authors.initials: R
authors.lastname: García-Carbonero
authors.affiliation: Medical Oncology Department, Doce de Octubre University Hospital (Center Affiliated to the Red Tematica de Investigacion Cooperativa en Cancer [RTICC], Instituto Carlos III, Spanish Ministry of Science and Innovation), Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Grávalos
authors.affiliation: Medical Oncology Department, Ramón y Cajal University Hospital (Center Affiliated to the Red Tematica de Investigacion Cooperativa en Cancer [RTICC], Instituto Carlos III, Spanish Ministry of Science and Innovation), Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Guillén-Ponce
authors.affiliation: Medical Oncology Department, Clinic San Carlos University Hospital (Center Affiliated to the Red Tematica de Investigacion Cooperativa en Cancer [RTICC], Instituto Carlos III, Spanish Ministry of Science and Innovation), Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Sastre
authors.affiliation: Oncology Department, Cancer Institute University Hospital (Fundacion Jimenez Diaz), Autonomous University of Madrid, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: García-Foncillas
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D006801:Humans; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D011788:Quality of Life; D016879:Salvage Therapy / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib
keywords: Antineoplasic agents; Colorectal neoplasms; Disease-free survival; Protein kinase inhibitors; Survival rate